In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas

Michal Entin-Meer, Xiaodong Yang, Scott R. VandenBerg, Kathleen R. Lamborn, Abraham Nudelman, Ada Rephaeli, Daphne Adele Haas-Kogan

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid derivative, pivaloyloxymethyl butyrate (AN-9), for the treatment of gliomas. Relative to control and single-modality treatments, the combination of AN-9 and radiation significantly inhibited tumor growth and prolonged time to failure in mice bearing glioma xenografts. The enhanced response to radiation was accompanied by inhibition of cellular proliferation and by increased phosphorylation of H2AX, implicating DNA double-strand breaks in the antineoplastic effects of AN-9 and radiation. The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalNeuro-Oncology
Volume9
Issue number2
DOIs
StatePublished - Apr 2007

Keywords

  • AN-9
  • Glioma
  • Histone deacetylase inhibitor
  • Radiation
  • Temozolomide
  • γ-H2AX phosphorylation

Fingerprint

Dive into the research topics of 'In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas'. Together they form a unique fingerprint.

Cite this